by myNEO Tx Admin | Apr 30, 2024 | Team events
Over the past few months, we organized our second table football spring cup, bringing together our team for some friendly competition β½οΈIn an intense battle for first place, Bruno Fant emerged victorious against Lore Van Oudenhove. In the small final, Lena Pfitzer...by myNEO Tx Admin | Feb 17, 2024 | Team events
Every week we gather for office workouts πββοΈ led by Lien Lybaert. It’s a great way to stay fit and foster a healthy work environment at myNEO Therapeutics. #WorkoutWednesdayby Wim Mees | Sep 21, 2023 | Team events
Congrats Lore Van Oudenhove, the winner of the first myNEO soccer cup! This summer we organised a table football cup where everyone of the team competed against each other. The third place playoff was won by Bruno Fant against Manon Montyne. Lore won the final after a...by Wim Mees | Jun 11, 2023 | Team events
Coming together is a beginning, staying together is progress, and working together is success! Just before summer we had a blast during the myNEO teambuilding where we had so much fun with different collaboration and competition games. While our team continues to...by Wim Mees | May 10, 2023 | Team events
Recently we enjoyed some delicious and freshly shaken, but not stirred, (m)(c)ocktails with the myNEO team. It was great catching up with everyone. #workhardplayhardThanks Deloitte for this great reward! #fast50 Enjoy the pictures !by Wim Mees | Oct 13, 2022 | Team events
At myNEO we know a company is only as strong as its team! Therefore, we recently built on that team relationship. In August we both had a team-BBQ together with our families and breakfast in the office with the board members.The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).